EnVivo Pharmaceuticals announced data in Neuropharmacology that indicate its compound EVP-6124 restored memory loss and improved memory function in preclinical models, making it a candidate for use as a long-term treatment to improve cognitive function in schizophrenia and Alzheimer's.
EVP-62124 is a potent and highly selective agonist of alpha-7 neuronal nicotinic acetylcholine receptors (nAChRs). It works alone or in combination with donepezil to restore memory loss and improve memory...
